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I. INTRODUCTION 
For years, marijuana was a taboo subject in America. Recently, 
however, medical marijuana has earned its place as the “scientifical, 
mystical one,” finding legalization in many states even in the face of 
federal prohibitions.1  Some laws authorizing even recreational use have 
been enacted.2 It is undeniable that marijuana, recreational or medical, is 
considered illegal under the federal Controlled Substances Act.3  With 
states passing their own laws regarding usage, there is confusion 
concerning the federal government’s enforcement priorities and its 
position with regard to medical marijuana.4  For purposes of this 
Comment, the terms medicinal and medical marijuana have the same 
common meaning and are used interchangeably. 
Part II of this Comment will address the state approaches to medical 
marijuana by presenting a brief overview of legislation in several key 
states to show how quickly support for usage has spread.  Part III will 
address the status of medical marijuana prior to 2015 and will discuss the 
federal Controlled Substance Act (“CSA”) and other Congressional 
measures regarding marijuana. It will also provide a brief overview of the 
singular Supreme Court case on the issue, Gonzales v. Raich.5  In addition, 
Part III will detail the role of the executive branch in marijuana 
reclassification as well as discuss internal guidance from the Obama 
Administration pertaining to prosecutorial discretion.  Part IV will explain 
the federal Farr-Rohrabacher Amendment and its impact on medical 
marijuana.  It will also discuss the Ninth Circuit’s analysis of the 
Amendment in United States v. McIntosh.6  This section further highlights 
                                                                                                                                     
 1 Cypress Hill, Dr. Greenthumb, on Cypress Hill IV (Ruffhouse Records 1998). 
 2 See Ballotpedia, Alaska Marijuana Legalization, Ballot Measure 2 (2014), 
https://ballotpedia.org/Alaska_Marijuana_Legalization,_Ballot_Measure_2_(2014); 
Ballotpedia, Maine Marijuana Legalization, Question 1 (2016), 
https://ballotpedia.org/Maine_Marijuana_Legalization,_Question_1_(2016); Ballotpedia, 
Massachusetts Marijuana Legalization, Question 4 (2016), 
https://ballotpedia.org/Massachusetts_Marijuana_Legalization,_Question_4_(2016); 
Ballotpedia, Nevada Marijuana Legalization, Question 1 (2016), 
https://ballotpedia.org/Nevada_Marijuana_Legalization,_Question_2_(2016). 
 3 21 U.S.C. § 801 et. seq. (2012). 
 4 Steve Contorno, Barack Obama Says It’s Up to Congress to Change How Feds 
Classify Marijuana, POLITIFACT (Feb. 4, 2014, 6:20 PM), 
http://www.politifact.com/truth-o-meter/statements/2014/feb/04/barack-obama/barack-
obama-says-its-congress-change-how-feds-cla/. 
 5 545 U.S. 1 (2005). 
 6 833 F.3d 1163 (9th Cir. 2016). 
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the conflict and contradiction of the federal prohibition on marijuana with 
the actions of the executive and legislative branches in response to the 
Farr-Rohrabacher Amendment. 
Part V will detail a scientific argument for expanding access to 
research for states in order to foster well-informed decisions over the fate 
of medical marijuana.  It will discuss several approaches the Trump 
Administration may take and the likelihood of success with each.  This 
Comment will argue that it would be most beneficial to suspend 
enforcement of the Controlled Substance Act, specifically as it applies to 
medical marijuana.  Suspension will be beneficial in order to allow the 
states to experiment legally and to ultimately take the lead on the future of 
medical marijuana, consistent with traditional norms of our federalist 
system. 
II. THE STATES AND MEDICAL MARIJUANA: A SPEEDY ACCEPTANCE 
Unlike the federal government, many states have passed medical 
marijuana laws that generally allow for the cultivation and use of 
marijuana when recommended by a doctor to treat serious conditions.7 
After a prohibition which originated in the early twentieth century, 
California became the first state to allow the use of medical marijuana in 
1996.8  The state’s Compassionate Use Act9 permits the use of medical 
marijuana for serious health conditions, as determined by a state health 
agency.10  It also allows for the treatment for other illnesses which may be 
assuaged by marijuana.11 Two years later, Washington state followed 
California and passed its own medical marijuana bill.12 Like California’s 
law, Washington’s bill made the drug available for certain conditions that 
are not relieved by standard treatment.13  Although Washington’s bill also 
created an affirmative defense against state prosecution, it did not provide 
protections against federal arrests.14  On the same day that Washington’s 
bill was enacted, Oregon passed a medical marijuana law with similar 
provisions and eligibility conditions as both California and Washington.15 
                                                                                                                                     
 7 Jay M. Zitter, Construction and Application of Medical Marijuana Laws and 
Medical Necessity Defense to Marijuana Laws, 50 A.L.R.6th 353, § 2 (2017). 
 8 Troey E. Grandel, One Toke over the Line: The Proliferation of State Medical 
Marijuana Laws, 9 U.N.H.L. REV. 135, 136 (2010). 
 9 Cal. Health & Safety Code § 11362.5 (Lexis 2017). 
 10 See Grandel, supra note 8 at 141–142. 
 11 Id. 
 12 Id. at 142 
 13 Id. 
 14 Id. 
 15 See Grandel, supra note 8 at 142–43. 
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Since then, a number of states have passed legislation allowing for 
“comprehensive public medical marijuana and cannabis programs.”16  In 
these states, patients are typically required to provide a doctor’s written 
authorization as well as obtain a prescription, subject to select conditions 
and diseases.17  Some states, such as Colorado, also allow for the limited 
use of Cannabidiol (“CBD”)18 products for medical reasons or as a legal 
defense.19  Alaska, Colorado, Oregon, Washington, and the District of 
Columbia have all authorized marijuana use in small amounts for 
recreational purposes.20  Other states, such as New Hampshire and 
Vermont have proposed legislation to legalize marijuana by removing 
criminal penalties for its use and possession.21  In the 2016 election cycle, 
four states voted and approved medical marijuana measures to expand or 
establish its availability for medical purposes.22  Despite all of these state 
reforms and initiatives, marijuana is still illegal under federal law. 
                                                                                                                                     
 16 State Medical Marijuana Laws, MEDICINAL CANNABIS CONFERENCE (Mar. 1, 2017), 
http://www.medicinalcannabisconference.com/?p=896.  The states include Alabama, 
Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, 
Illinois, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, Montana, Nevada, North Dakota, New Hampshire, New 
Jersey, New Mexico, New York, North Carolina, Oklahoma, Rhode Island, South Carolina, 
Tennessee, Texas, Utah, Vermont, Virginia, Wisconsin, and Wyoming, the District of 
Columbia, Guam, and Puerto Rico.  See Dean M. Nickles, Federalism and State Marijuana 
Legislation, 91 NOTRE DAME L. REV. 1253 (2016); See also The National Conference of 
State Legislatures, Medical Marijuana Laws, http://www.ncsl.org/research/health/state-
medical-marijuana-laws.aspx. 
 17 Beth P. Zoller, Hazy Future: Reconciling Federal and State Laws on Marijuana 
Use, XpertHR Legal Insight 9666 (Lexis 2017). 
 18 Unlike delta-9 tetrahydrocannabinol (“THC”), which causes the high, CBD is not 
intoxicating and does not cause a high; it is cited as one of the reasons why the restrictions 
on marijuana should be relaxed.  See Nora Volkow,  
Researching Marijuana for Therapeutic Purposes: The Potential Promise of Cannabidiol (CBD), THE 
HUFFINGTON POST (Jul. 23, 2016), http://www.huffingtonpost.com/nora-
volkow/cannabidiol_b_7834066.html. 
 19 See Volkow, supra note 18. 
 20 See Ballotpedia, supra note 2. 
 21 See Zoller, supra note 17. 
 22 Katy Steinmetz and David Johnson, Election 2016: States Where Marijuana Is on 
the Ballot, TIME (Nov. 4, 2016), http://time.com/4557417/election-2016-marijuana-pot-
legal-ballot/; See also  Ballotpedia, North Dakota Medical Marijuana Legalization, 
Initiated Statutory Measure 5 (2016), 
https://ballotpedia.org/North_Dakota_Medical_Marijuana_Legalization,_Initiated_Statut
ory_Measure_5_(2016); Ballotpedia, Florida Medical Marijuana Legalization, Amendment 
2 (2016),  
https://ballotpedia.org/Florida_Medical_Marijuana_Legalization,_Amendment_2_(2016); 
Ballotpedia, Arkansas Medical Marijuana Amendment, Issue 6 (2016), 
https://ballotpedia.org/Arkansas_Medical_Marijuana_Amendment,_Issue_6_(2016); 
Ballotpedia, Montana Medical Marijuana Initiative, I-182 (2016), 
https://ballotpedia.org/Montana_Medical_Marijuana_Initiative,_I-182_(2016). 
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III. THE STATUS OF MEDICAL MARIJUANA UNDER FEDERAL LAW 
THROUGH 2015 
The federal government prohibits the use of marijuana completely, 
even if used for medicinal purposes.23 However, a closer examination 
shows that there are discrepancies amongst the three branches regarding 
how strictly this prohibition is viewed. Subsection A will address the 
Congressional approach to medical marijuana. It will detail relevant 
sections of the CSA as well as illustrate more recent legislative efforts, 
suggesting that at least some members of the legislative branch are open 
to the acceptance of medical marijuana. Subsection B will review the 
Supreme Court’s stance on medical marijuana as cemented in Gonzales v. 
Raich.24 Finally, Subsection C will discuss the executive branch’s role 
under the CSA, including the various agencies involved in the 
rescheduling considerations to remove Marijuana from the list of Schedule 
I drugs as well as the enforcement of federal law, including internal 
guidance issued on medical marijuana. This section will also address a 
failed attempt by the executive and the legislative branches to reclassify 
medical marijuana. 
A. Congress 
Marijuana is illegal under federal law.  More specifically, it is highly 
regulated under the CSA and is classified as a Schedule I drug, the most 
restrictive classification.25  The CSA classifies drugs as Schedule I if they 
(1) have a “high potential for abuse,” (2) have “no currently accepted 
medical use in treatment in the United States,” and if (3) “[t]here is a lack 
of accepted safety for use of the drug . . . under medical supervision.”26  
Schedule I drugs may be lawfully obtained and used only by doctors who 
have submitted a detailed research protocol for approval to the Food and 
Drug Administration (“FDA”), and who agree to abide by strict rules 
pertaining to recordkeeping and storage rules.27  Further, the Attorney 
General, under the authority of the Drug Enforcement Administration 
(“DEA”) may reschedule a drug if he or she finds that the drug no longer 
meets the criteria under the schedule for which it has been assigned.28  This 
decision is based upon “[s]cientific evidence of [the drug’s] 
                                                                                                                                     
 23 21 U.S.C. § 812(c)(10) (2012). 
 24 545 U.S. 1 (2005). 
 25 See 21 U.S.C. § 812, Supra note at 23. 
 26 Id.  § 812(b)(1). 
 27 Id. 
 28 Id. 
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pharmacological effect, if known,” and “[t]he state of current scientific 
knowledge regarding the drug or other substance.”29 
Drugs classified under Schedule II are those that (1) have a high 
potential for abuse; have a currently accepted medical use as treatment or 
are currently accepted with severe restrictions; and (3) if abused, may lead 
to severe psychological or physical dependence.30  For a drug to be 
classified as Schedule III, IV, or V, those which are deemed acceptable for 
medical treatment, the Attorney General must verify the following: (1) the 
drug’s chemistry is known and reproducible; (2) there are adequate safety 
studies; (3) there are adequate and well-controlled studies proving 
efficacy; (4) the drug is accepted by qualified experts; and (5) there is 
scientific evidence widely available.31 
For over forty-five years, the federal government has exercised 
almost exclusive control over research-grade marijuana, and has refused 
to allow for privately-funded and FDA-approved operations on research-
grade marijuana.32  While marijuana has throughout history been 
extensively used and researched,33 no Attorney General has taken the 
initiative to modify the drug’s current classification as Schedule I.34 
In March 2015, over a year before the DEA issued its official refusal 
to reclassify medical marijuana,35 Republican House Representative Scott 
Perry (PA) introduced the Charlotte’s Web Medical Help Act.36  The Act 
called for the exclusion of “therapeutic hemp and cannabidiol from the 
definition of marihuana [sic], and for other purposes.”37  The bill’s 
namesake was a seven-year-old girl, Charlotte Figi, who suffered from 
Dravet Syndrome, a rare form of epilepsy.38  After moving to Colorado 
                                                                                                                                     
 29 Ams. for Safe Access v. DEA, 706 F.3d 438, 441 (D.C. Cir. 2013). 
 30 § 812(b)(2) (2012). 
 31 Ams. for Safe Access, 706 F.3d. at 441. 
 32 Ruth C. Stern and J. Herbie DiFonzo, The End of the Red Queen’s Race: Medical 
Marijuana in the New Century, 27 QUINNIPIAC L. REV. 673, 707 (2009). 
 33 See Grandel, supra note 8 at 136–39. 
 34 See generally Department of Justice, Drug Enforcement Administration, 21 C.F.R. 
Chapter 11, Docket No. DEA426, Denial of Petition to Initiate Proceedings to Reschedule 
Marijuana (Aug. 12, 2016), available at 
https://www.federalregister.gov/documents/2016/08/12/2016-17954/denial-of-petition-to-
initiate-proceedings-to-reschedule-marijuana. [Hereinafter 2016 DEA Denial]. 
 35 Id. 
 36 Charlotte’s Web Medical Hemp Act of 2014, H.R. 5226, 113th Cong. (2014). 
 37 Id. 
 38 Hannah Osborne, Charlotte Figi: The Girl Who is Changing Medical Marijuana 
Laws Across America, INTERNATIONAL BUSINESS TIMES (Jun. 20, 2014), 
http://www.ibtimes.co.uk/charlotte-figi-girl-who-changing-medical-marijuana-laws-
across-america-1453547; Matt Ferner, House Bill Would Legalize ‘Charlotte’s Web’ 
Medical Marijuana, THE HUFFINGTON POST (Jul. 29, 2014), 
http://www.huffingtonpost.com/2014/07/28/medical-marijuana-
legalization_n_5627810.html. 
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with her family and obtaining the help of a non-profit organization, 
Charlotte’s seizures were successfully treated “with a strain of high-CBD, 
low-THC medical cannabis called ‘Charlotte’s Web.’  Traditional 
pharmaceuticals failed to help Charlotte.”39 In general, there is genuine 
debate over the actual medicinal advantages for marijuana in general.40  
That being said, it is counterintuitive to hinder additional research on the 
success of THC-based extracts in treating serious conditions, such as 
epilepsy (particularly in children); this research could yield real medical 
benefits, which may save the lives of those for whom traditional treatment 
options do not work.  As of the writing of this Comment, Representative 
Perry’s act has not advanced beyond referral to the Subcommittee on 
Crime, Terrorism, Homeland Security, and Investigations.41 
B. The Supreme Court 
In 2005, the Supreme Court decided its only medical marijuana case 
to date.42 The respondents in Gonzales v. Raich were residents of 
California who sought relief from various medical conditions through 
procurement of medical marijuana, an action that was permissible under 
the state’s Compassionate Care Act.43  After unsuccessful results from 
conventional drugs, board-certified family practitioners treated the 
respondents with marijuana, as it was the only drug that provided relief.44  
In August 2002, county deputy sheriffs and DEA agents came to the house 
of one of the respondents, conducted a thorough investigation and 
concluded that her use of marijuana was lawful under California law.  Still, 
the agents seized and destroyed all six cannabis plants present.45  At trial, 
the respondents sought injunctive relief from enforcement under the CSA 
given the conflict between state law and their legitimate and serious 
medical conditions.46  They argued that enforcing the CSA was a violation 
of various constitutional principles, as well as and the doctrine of medical 
necessity.47 
                                                                                                                                     
 39 Id. 
 40 See 2016 DEA Denial, supra note 34; see also Craig Press, Kelly Knupp, and Kevin 
Chapman, Parental Reporting of Response to Oral Cannabis Extracts as Adjunctive 
treatment for Medically Refractory Epilepsy, in American Epilepsy Society Annual 
Meeting Abstracts (Abst. 1.326, 2014), available at 
https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/1868031. 
 41 Charlotte’s Web Medical Access Act of 2015, H.R. 1635, 114th Cong. (2015). 
 42 Gonzales v. Raich, 545 U.S. 1 (2005). 
 43 Id. at 6–7. 
 44 Id. at 7. 
 45 Id. 
 46 Id. 
 47 Id. at 8. 
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The Supreme Court was not persuaded.  In Justice Stevens’ majority 
opinion, the Court applied the rational basis test, and found that “Congress 
was acting well within its authority to ‘make all [laws] which shall be 
necessary and proper’” by enacting the CSA; this justified the federal 
government’s seizure of the respondent’s marijuana.48  Echoing Wickard 
v. Filburn, the Court strongly emphasized that Congress possesses the 
authority to regulate interstate commerce, even in instances where non-
commercial, intrastate activities could undercut regulation of the interstate 
market.49  In essence, Congress may still regulate a “local” activity 
because that activity may have a substantial economic effect on interstate 
commerce.50  The Gonzales Court determined that the CSA applied to the 
respondents by virtue of the Supremacy Clause, and that “Congress had a 
rational basis for concluding that leaving home-consumed marijuana 
outside federal control would similarly affect price and market 
conditions.”51 
Gonzales, however, was not a unanimous decision.  Writing for the 
dissent, Justice O’Connor was critical of the reliance on Wickard and 
rallied for federalism.52  In reassessing the scope of the Commerce Clause 
in tandem with the CSA to account for medical use of marijuana, Justice 
O’Connor reasoned that respondents’ private actions did not have a 
substantial impact on commerce because their private action failed the 
Wickard steam of commerce test; their private actions could not, therefore, 
impact the national market.53  She also noted that the majority’s 
application of the Necessary and Proper Clause did still require the federal 
government to honor “basic constitutional principles.”54  Further, Justice 
O’Connor argued that Wickard “did not hold or imply that personal-sized 
or small-scale productions are always economic and are automatically 
within Congress’s reach.”55 
Justice O’Connor also proposed that medical marijuana be regulated 
separately from general recreational use, suggesting that the majority’s 
reading of the CSA was far too broad and creates unnecessary federalism 
issues.56  In her view, the action by the federal government was 
                                                                                                                                     
 48 Gonzales, 545 U.S. at 22 (citing U.S. CONST. art. 1, 8, cl. 18).  See also Casey L. 
Carhart, Will the Ever-Swinging Pendulum of Commerce Clause Interpretation Ever Stop? 
A Casenote on Gonzales v. Raich, 27 WHITTIER L. REV. 833, 835 (2006). 
 49 Gonzales, 545 U.S. at 17–18 (citing Wickard v. Filburn, 317 U.S. 111 (1942)). 
 50 Wickard, 317 U.S. at 124–25. 
 51 Gonzales, 545 U.S. at 19, 29. 
 52 Id. at 42 (O’Connor, J., dissenting). 
 53 See Carhart, supra note 48, at 848. 
 54 Id. at 847. 
 55 Gonzales, 545 U.S. at 51 (O’Connor, J., dissenting). 
 56 Id. at 48; see also Carhart, supra note 48 at 847. 
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unconstitutional because California voters had decided—by ballot and by 
legislation—to legalize the drug, and thus any interference on the part of 
the federal government would deny a state the ability to give effect to its 
own laws.57  For Justice O’Connor, it was within the states’ core powers 
to define their own criminal law and to protect their citizens.58  The federal 
government’s power to, at will, interfere with a state’s traditional police 
power is problematic for any state wishing to decriminalize or legalize 
marijuana.  Justice O’Connor argued that the Court’s decision in Gonzales 
is “irreconcilable” with its own prior precedent in cases not dealing with 
marijuana.59  Post-Gonzales, it appears, states have taken Justice 
O’Connor’s dissent seriously.  The majority’s ruling has not stopped states 
like Rhode Island, Montana, Michigan, New Jersey, or the District of 
Columbia from enacting their own medical marijuana laws in the 
aftermath of this decision.60 
C. The Executive Branch 
The executive branch enforces the regulation of marijuana through 
various agencies.  Under 28 U.S.C. § 811, the Attorney General, of the 
Department of Justice (“DOJ” or “the Department”) may add or remove 
drugs from the schedules as long as there is, for example, evidence of 
potential for abuse.61  Congress, however, may decide to reschedule 
marijuana or remove it entirely from the Controlled Substance Act.62  The 
DEA, the FDA, the Department of Health and Human Services (“HHS”), 
and the National Institute on Drug Abuse (“NIDA”) are all important 
agencies in medical marijuana rescheduling considerations.  The DEA 
gathers necessary data on a drug and subsequently requests a scientific and 
medical evaluation and scheduling recommendation from Secretary of 
HHS.63  Administrative responsibilities for evaluating a substance for 
control under the CSA are performed by the FDA, with NIDA’s 
concurrence.64 
                                                                                                                                     
 57 Wilson Ray Huhn, The Constitutional Jurisprudence of Sandra Day O’Connor: A 
Refusal to “Foreclose the Unanticipated”, 39 AKRON L. REV. 373, 413. 
 58 Gonzales, 545 U.S. at 43 (O’Connor, J., dissenting). 
 59 Id.  For additional discussions regarding the use and limitations of Congress’s ability 
to act pursuant to the Commerce Clause, See United States v. Lopez, 514 U.S. 549, 551 
(1995) (finding that possession itself is not commercial activity); See also United States v. 
Morrison, 529 U.S. 598, 611 n.4 (2000) (intrastate activities that may be regulated by 
Congress must be of an “apparent commercial character”). 
 60 Grandel, supra note 8 at 139; see also Cal. Health & Safety Code § 11362.5 (1996). 
 61 21 U.S.C. 811 (a)(1)(A) (2012), see also 2016 DEA Denial, supra note 34. 
 62 See Contorno, supra note 4. 
 63 21 U.S.C. § 811 (b) (2017). 
 64 Memorandum of Understanding with the National Institute on Drug Abuse 50 FR 
9518-02 (March 8, 1985). 
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The DOJ has seen a fluctuation in domestic marijuana seizures since 
1984.65 In 2014, the total number of seizures was at its lowest since 1986 
with 74,225.66 The decline late in the Obama Administration potentially 
corresponds with the three internal guidance memoranda utilized by the 
Department. Beginning in 2009, the DOJ issued memos to its prosecutors 
regarding their responsibilities in terms of states with medical marijuana 
laws.  In the initial memorandum, then-Deputy Attorney General David 
Ogden emphasized that the priority of the Department was to prosecute 
criminal enterprises that create illegal markets to sell marijuana as opposed 
to prosecuting individuals with serious illnesses who use marijuana 
consistent with state law.67  The DOJ was to continue its due diligence in 
investigations, but it would not be quick to prosecute marijuana usage 
claims in states that allowed medical use.68  Ogden cautioned, however, 
that compliance in such states may be done to mask illegal operations, and 
that prosecutions should be made on a case-by-case basis in order for the 
federal government to remain consistent with guidelines on resource 
allocations and priorities.69 
In 2013 and 2014, the Department clarified its earlier guidance and 
noted that while state laws authorizing marijuana production, distribution, 
and possession contrast with federal-state narcotics enforcement, the 
federal government is less threatened by states that have implemented 
strong, effective regulatory and enforcement schemes to oversee various 
forms of marijuana usage.70 The subsequent memos once again expressed 
prosecutorial discretion in instances of chronically ill individuals abiding 
by state law as opposed to commercial enterprises; they noted that if states 
                                                                                                                                     
 65 Drug Enforcement Administration, Statistics & Facts, 
https://www.dea.gov/resource-center/statistics.shtml. 
 66 See id.; see also Drug Enforcement Administration, 2015 Final Domestic Cannabis 
Eradication/Suppression Program Statistical Report, available at 
https://www.dea.gov/ops/cannabis_2015.pdf; 2014 Domestic Cannabis 
Eradication/Suppression Statistical Report, available at 
https://www.dea.gov/ops/cannabis_2014.pdf. 
 67 David Ogden, Memorandum for Selected United States Attorneys re: Investigations 
and Prosecutions in States Authorizing the Medical Use of Marijuana, Oct. 19, 2009, 
available at https://www.justice.gov/opa/blog/memorandum-selected-united-state-
attorneys-investigations-and-prosecutions-states [hereinafter Ogden Memo]; James M. 
Cole, Memorandum for All United States Attorneys re: Guidance Regarding Marijuana 
Enforcement, Aug. 29, 2013, available at 
https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf [hereinafter 
2013 Cole Memo]; James M. Cole, Memorandum for All United States Attorneys re: 
Guidance Regarding Marijuana Related Financial Crimes, Feb. 14, 2014, available at 
http://www.dfi.wa.gov/documents/banks/dept-of-justice-memo.pdf [hereinafter 2014 Cole 
Memo] 
 68 See Ogden Memo, supra note 67. 
 69 Id. 
 70 See 2014 Cole Memo, supra note 67. 
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lack “robust” enforcement efforts, the federal government may challenge 
the regulatory structure as well as pursue legal action.71  With this 
guidance, the federal government may take action against states, despite 
the presence of strong state regulatory structures, if certain conduct or 
people threaten federal priorities.72  The discretion allotted in the guidance 
and in state laws does not constitute valid defenses to any action taken by 
the federal government in terms of enforcement.73  The federal 
government may always act to enforce, but the guidance gives states and 
marijuana users insight as to when the federal government is likely to do 
so.  The DOJ charged its attorneys with monitoring conditions in the states 
in order to assess when to use its limited budget for prosecutions, but it 
has not provided specificity as to how it will monitor users within states 
with medical marijuana laws.74 
Simply because there is prosecutorial discretion regarding 
enforcement does not mean the DEA under President Obama was eager to 
reclassify marijuana from Schedule I.  In November 2011, then-Governors 
Lincoln D. Chafee (RI) and Christine O. Gregoire (WA) petitioned the 
DEA to reclassify marijuana away from Schedule I and repeal the relevant 
rules and regulations that kept it as such.75  The petition stated that 
“cannabis has an accepted medical use in the United States, is safe for use 
under medical supervision, and has a relatively low abuse potential 
compared to other Schedule II drugs.”76  The DEA requested scientific and 
medical evaluation and schedule recommendations from HHS, which 
ultimately found that marijuana possesses a high potential for abuse, has 
no accepted medical use in the United States, and lacks the appropriate 
level of safety for use under medical supervision.77  The DEA formally 
rejected the request to reclassify marijuana in July 2016.78  In its report, 
the agency noted that the FDA approval of a New Drug Application is not 
the only means through which a drug can be determined to have an 
                                                                                                                                     
 71 Id. 
 72 See 2014 Cole Memo, supra note 67. 
 73 Id. 
 74 See generally U.S. Gov’t Accountability Office, GAO-16-1, Report to 
Congressional Requesters: State Marijuana Legalization, DOJ Should Document Its 
Approach to Monitoring the Effects of Legalization (2015), 
http://www.gao.gov/assets/680/674464.pdf. 
75 U.S. Department of Justice, Schedule of Controlled Substances: Maintaining Marijuana 
in Schedule I of the Controlled Substance Act (2016), 1, 
https://www.deadiversion.usdoj.gov/schedules/marijuana/Maintaining%20Marijuana%20
in%20Schedule%20I%20of%20the%20Controlled%20Substances%20Act.pdf. 
 76 Id. 
 77 Id. at 2. For discussion regarding the specific reasoning the DEA gave for these 
categories, see id. at 54–75. 
 78 See generally id. 
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accepted medical use in treatment in the United States.79  Citing to Alliance 
for Cannabis Therapeutics v. DEA,80 the DEA outlined a five-part test to 
determine if a drug has a “currently accepted medical use”81 in the United 
States: “(1) the drug’s chemistry must be known and reproducible . . . ; (2) 
there must be adequate safety studies . . . ; (3) there must be adequate and 
well-controlled studies proving efficacy . . . ; (4) the drug must be 
accepted by qualified experts . . . ; and (5) the scientific evidence must be 
widely available[.]”82 
In examining these prongs, HHS concluded that marijuana does not 
meet any of the requirements.83  More specifically, the HHS determined 
that marijuana’s chemistry is such that (1) a standardized dose cannot be 
created due to the irreproducibility of the drug; that the variation of the 
drug’s chemistry complicates safety evaluations; (2) that there are no 
adequate or well-controlled studies to document marijuana’s efficacy; (3) 
that there is currently no evidence of a consensus amongst qualified 
experts that marijuana is an effective and appropriate treatment measure; 
(4 and 5) and that the current data on the drug is insufficient to allow for 
scientific scrutiny, emphasizing that the chemistry of a specific cannabis 
strain suggesting standardization and reproducibility does not exist.84  
Despite the efforts of Governors Chafee and Gregorie to show that there 
was evidence of acceptance in the medical community and that the 
chemistry is known and reproducible, the DEA found that “informative, 
conclusions on long-term use of marijuana cannot be applied to the general 
population.”85 
The federal government’s refusal to reconsider its stance is 
interesting (or noteworthy), in light of the fact that marijuana is the only 
Schedule 1 drug that non-DEA-licensed private laboratories and 
researchers are not allow to produce in a scientific study environment.86  
In 2007, a DEA Administrative Law Judge recommended a University of 
Massachusetts professor be granted permission by the DEA to grow 
marijuana for medical purposes after her petition had been pending for six 
years.87  The Administrative Law Judge found “the existing supply of 
licensed cannabis inadequate, [deeming the] application to cultivate 
marijuana for research purposes to be ‘in the public interest’ and 
                                                                                                                                     
 79 Id. at 32. 
 80 15 F.3d 1131 (D.C. Cir. 1994). 
 81 See 2016 DEA Denial, supra note 34 at 53700. 
 82 Id. at 53739. 
 83 Id. at 53700. 
 84 Id. at 53700–01. 
 85 Id. at 53760; see also infra Part V. 
 86 See Stern and DiFonzo, supra note 32 at 707. 
 87 Id. 
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recommended it be granted.”88  The determination, however, was subject 
to review by the DEA Administrator and, as with the Administrative Law 
Judge’s earlier decision on rescheduling, was rejected.89  However, not all 
those who seek authorization to research are denied; they may just have to 
wait a decade or so.90 
In 2008, the American College of Physicians prepared a position 
paper strongly supporting “increased research and evaluation on 
marijuana’s therapeutic benefits.”91  It boldly noted that the overly strict 
federal government oversight created a “clear discord . . . between the 
scientific community and federal, legal, and regulatory agencies over the 
medical value of marijuana, which impedes the expansion of research.”92  
Similarly, in 2009, the American Medical Association put forth a report 
cited by Governors Chafee and Gregorie’s 2011 request.93  The report 
accepted marijuana’s safety and efficacy, but cautioned that: (1) it was not 
endorsing state-based medical marijuana programs; (2) was not 
advocating for the legalization of marijuana, and; (3) was not suggesting 
that scientific evidence on the therapeutic use of cannabis meets the same 
and current standards for a prescription drug product.94 
IV. THE FARR-ROHRABACHER AMENDMENT: THE FEDERAL 
GOVERNMENT VS. THE FEDERAL GOVERNMENT IN 2015 AND BEYOND 
Through 2015, the states that passed their own legislation legalizing 
medical marijuana did so despite federal prohibitions.  Congress, which 
has outlawed marijuana under the CSA, has also proposed laws that would 
allow for the use of marijuana-derivatives to treat medical conditions.95  
Likewise, memoranda exists from the DOJ promoting prosecutorial 
discretion in states that have legalized medical marijuana, despite the 
Department’s role in enforcing the CSA.96  Inevitably, the consequences 
                                                                                                                                     
 88 Id. 
 89 Id. 
 90 See also Janet Burns, Trump Extends Cannabis Protections ‘Til December as Plans 
for Study, States Remain Hazy, Forbes (Date of 
Access), https://www.forbes.com/sites/janetwburns/2017/09/25/trump-budget-extends-
cannabis-protections-til-december-as-plans-for-study-states-remain-hazy/#c77e5c947ffe  
(“Last year, the DEA began accepting applications to grow more cannabis for research, 
and it’s reportedly received 25 such proposals as of this month.  In order to proceed, 
however, researchers would need the Justice Department’s approval, and have so far come 
up entirely short.”) (last visited Jan. 1, 2018). 
 91 Stern DiFonzo, supra note 32 at 708. 
 92 Id. (internal citation omitted). 
 93 See 2016 DEA Denial, supra note 34 at 53756. 
 94 Id. (internal citations omitted). 
 95 See supra Part III, Section A. 
 96 See supra Part III, Section C. 
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of conflicting enforcement policies have led to a shift in oversight.  In 
2015, Congress passed a spending bill that included the Farr-Rohrabacher 
Amendment, which gave states with medical marijuana laws a reprieve 
from inconsistent federal enforcement.97  Subsection A will detail the Farr-
Rohrabacher Amendment itself.  Subsection B will explore the 
implications of the Amendment, including McIntosh, a case in which the 
Ninth Circuit upheld the constitutionality of the Amendment.98  Section C 
will focus on the aftermath of McIntosh as faced by Congress and by the 
executive branch. 
A. The Farr-Rohrabacher Amendment 
In December 2015, Congress passed the Consolidated 
Appropriations Act 2016, which President Obama signed on the same 
day.99  Section 538 is referred to as the Farr-Rohrabacher Amendment 
(“the Amendment” or “§ 538”).100  It was co-sponsored by Democratic 
Representative Sam Farr (CA) and Republican Representative Dana 
Rohrabacher (CA).  The Amendment took many forms, while continually 
offered for debate in the House of Representatives since 2003.101  While 
the Amendment first formally appeared in the 2015 omnibus bill, it was 
the 2016 Amendment, containing the same language, which was at issue 
in McIntosh, discussed in Subsection B below.102  The Amendment 
provides as follows: 
None of the funds made available in this Act to the Department of 
Justice may be used, with respect to any of the States of Alabama, Alaska, 
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, 
Hawaii, Illinois, Iowa, Kentucky, Louisiana, Maine, Maryland, 
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, 
Nevada, New Hampshire, New Jersey, New Mexico, New York, North 
Carolina, Oklahoma, Oregon, Rhode Island, South Carolina, Tennessee, 
Texas, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming, 
                                                                                                                                     
 97 See infra, Part IV, Section A. 
 98 833 F.3d 1163. 
 99 Consolidated Appropriations Act 2016, Pub. L. No. 114-113, 114 Cong. (2015). 
 100 In the previous spending bill, Consolidated and Further Continuing Appropriations 
Act 2015, Pub. L. No. 113-235, 113 Cong. (2014), the Amendment is located at Section 
538, available at: https://www.congress.gov/113/plaws/publ235/PLAW-113publ235.pdf. 
 101 Douglas H. Fischer, Clearing the Smoke Around the Farr-Rohrabacher Amendment, 
LAW360.COM (Mar. 10, 2015, 12:35 PM), 
https://www.law360.com/articles/628782/clearing-the-smoke-around-the-farr-
rohrabacher-Amendment. 
 102 See United States v. Firestack-Harvey, 2014 U.S. Dist. LEXIS 60959, 2014 WL 
1744255 (relying on a previous iteration of the appropriation bill).  Reader should note that 
the Amendment language is consistent in the appropriations bills. See also Fischer, supra 
note 101. 
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or with respect to the District of Columbia, Guam, or Puerto Rico, to 
prevent any of them from implementing their own laws that authorize the 
use, distribution, possession, or cultivation of medical marijuana.103 
By pulling on the purse strings, Congress is protecting states with 
valid laws only from prosecution.  It does not prohibit the federal 
government from surveilling states irrespective of marijuana laws or from 
prosecuting individuals in those states without medical marijuana 
legalization laws.104  The Amendment was included in past appropriation 
bills105  and was allotted for in the 2017 Appropriations Acts.106  At the 
time of the 2016 Appropriations Bill, Representative Farr remarked that 
the Amendment served not only to protect the states with medical 
marijuana laws from federal intrusion, but also residents who lawfully 
comply with those state laws from apprehension by the federal 
government.107 Representative Farr cited a Pew Research Center survey 
which found that 61% of Republicans and 76% of Independents favored 
legalization of medical marijuana and argued that shifting social opinions 
were influential in including this Amendment.108  Much of the 
Congressional record reflects similar arguments made in the 2016 DEA 
report,109 namely, that there is no medical evidence for such claims of 
efficacy and that the drug is highly addictive.110  Ultimately, the arguments 
                                                                                                                                     
 103 See supra note 99 at § 542. 
 104 See infra Part IV, Section C; see also Daniel J. Hurteau, et al., Confusion Persists 
over Medical Marijuana Enforcement, LAW360.COM (Jan. 15, 2015, 2:12 PM), 
https://www.law360.com/articles/613191/confusion-persists-over-medical-marijuana-
enforcement. 
 105 See supra note 100. 
 106 See 114 P. L. 114-223 (Lexis 2017) (“The following sums are hereby appropriated, 
out of any money in the Treasury not otherwise appropriated, and out of applicable 
corporate or other revenues, receipts, and funds, for the several departments, agencies, 
corporations, and other organizational units of Government for fiscal year 2017, and for 
other purposes . . . [including]: The Commerce, Justice, Science, and Related Agencies 
Appropriations Act, 2016 (division B of Public Law 114–113)”).  To avoid a government 
shutdown following the appropriation’s September 20, 2016 expiration date, Congress 
extended the amendment under the Continuing Appropriations and Military Construction, 
Veterans Affairs, and Related Agencies Appropriation Act, 2017, and Zika Response and 
Preparedness Act. See also 114 P. L. 114-254 (further extending appropriations through 
April 28, 2017). 
 107 160 Cong. Rec. H4982-85 (daily ed. May 29, 2014); see also Brief of Members of 
Congress Rohrabacher (R-CA) and Farr (D-CA) as Amici in Support of Charles C. Lynch’s 
Motion for Rehearing En Banc, United States v. Lynch, Nos. (9th Cir. 2015) (Nos. 10-
50219, 10-50264). 
 108 160 Cong. Rec. H4982-85, H4983 (daily ed. May 29, 2014); see also Public Support 
for Legalizing Medical Marijuana, Pew Research Center (Apr. 1, 2010), 
http://www.people-press.org/2010/04/01/public-support-for-legalizing-medical-
marijuana/. 
 109 See supra Part III. See generally 2016 DEA Denial, supra note 34. 
 110 160 Cong. Rec. H4982-85, H4985 (daily ed. May 29, 2014). 
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were not persuasive and the House of Representatives passed the 
appropriations bill with the Amendment in it on April 30, 2015, by a vote 
of 255-163.111  Of those 255 votes of “yea,” 236 were Republicans and 19 
were Democrats.112 On November 10, 2015, the Senate passed the bill with 
changes, which required the House’s approval.113  The collective bill was 
approved on December 18, 2015 with a vote in the Senate of 65-33, with 
27 Republicans and 37 Democrats agreeing with the passage.114 
Numerous questions arise from such vague language concerning 
enforcement, executive power, and the fact that federal government’s 
attention is still not fully diverted from marijuana, even for medical 
purposes.115  As will be shown in Subsection B, courts engage in narrow 
interpretation when there is a dispute over congressional intent, since 
Amendments do not follow the same legislative process as regular laws 
and the stakes are very high.116 Appropriation Amendments are a clever, 
though controversial, way for Congress to exert dominance over executive 
power.117 
B. United States v. McIntosh: The Ninth Circuit’s Dance with Mary 
Jane 
In August 2016, the Ninth Circuit upheld the constitutionality of the 
Farr-Rohrabacher Amendment.118  In McIntosh, ten cases were 
consolidated on interlocutory appeals and petitions for writs of mandamus 
from appellants who were indicted for various infractions under the 
CSA.119  In McIntosh, five co-defendants allegedly ran four marijuana 
stores in the Los Angeles and San Francisco areas and were indicted for 
conspiracy to: manufacture; possess with intent to distribute; and 
distribute more than 1,000 marijuana plants in violation of the CSA.120  In 
United States v. Lovan, the DEA and the Fresno County Sheriff’s Office 
executed a federal search warrant on land located in Sanger, California, 
where more than 30,000 marijuana plants were found on the property, 
leading to the indictment of four co-defendants in violation of the CSA.121  
                                                                                                                                     
 111 Actions Overview H.R.2029 – 114th Congress (2015-2016), available at 
https://www.congress.gov/bill/114th-congress/house-bill/2029/actions. 
 112 Id. 
 113 Consolidated Appropriations Act, H.R. 2029, 114th Cong. (2016). 
 114 Id. 
 115 See Hurteau et al., supra note 104. 
 116 Id. 
 117 See Fischer, supra note 101. 
 118 McIntosh, 833 F.3d at 1168. 
 119 Id. at 1169–70. 
 120 Id. at 1169. 
 121 Id. 
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In the final consolidated case, United States v. Kynaston, five co-
defendants faced charges relating to Washington State’s Controlled 
Substance Act, which lead to an ultimate indictment under the CSA, as 
well as illegal firearm possession.122  In McIntosh and Kynaston, the lower 
courts found that the defendants did not meet the burden necessary to 
demonstrate compliance with state medical marijuana laws, and denied the 
motions to dismiss or to enjoin on the basis of the Amendment from the 
bench.123  In Lovan, the court found that a jury trial was necessary to 
determine if defendants complied with state law, and that the motion to 
dismiss would only be revisited post-trial.124 
On appeal, the Ninth Circuit noted that these cases were unusual, as 
federal criminal prosecutions do not typically provide for injunctive relief 
and interlocutory appeals for ongoing litigation.125  Congress’s enactment 
of the Amendment led the court to note that it is “the exclusive province 
of the Congress not only to formulate legislative policies and mandate 
programs and projects, but also to establish [its] relative priority for the 
Nation.”126 Moreover, the court stated that, once Congress delegates its 
powers or otherwise prioritizes a certain area, it is up to courts to enforce 
such policies when enforcement is sought.127  As such, the court found that 
it could not “ignore the judgment of Congress”, one that was “deliberately 
expressed in legislation” and is authorized to exercise jurisdiction if a 
district court denies a request for injunctive relief.128  The court limited the 
scope of its analysis in a footnote, stating that it did not need to decide how 
the district courts should resolve claims that the DOJ is in violation of the 
Amendment. 129 
The court based its decision on several factors, including its 
understanding of the Amendment text, and then engaged in statutory 
interpretation.130  In addressing the Amendment, the court stated, “[n]o 
money shall be drawn from the treasury, but in consequence of 
appropriations made by law . . . .”131  Appellants argued, and the court 
agreed, that if the DOJ were spending money in violation of § 542 of the 
Amendment, it would be in violation of the Constitution, furthering their 
                                                                                                                                     
 122 Id. 
 123 Id. 
 124 McIntosh, 833 F.3d at 1169. 
 125 Id. at 1172. 
 126 Id. (citing Tenn. Valley Auth. v. Hill, 437 U.S. 153, 194 (1978)). 
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 128 Id. (citing United States v. Oakland Cannabis Buyers’ Co-op., 532 U.S. 483, 497 
(2001)). 
 129 Id. at 1172, n.2. 
 130 McIntosh, 833 F.3d at  1169–75. 
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claims pertaining to separation of powers.132  In his motion to dismiss the 
federal government’s complaint, individual appellant McIntosh argued 
given that the government’s own complaint noted that the defendants were 
operating under California’s state medical marijuana laws with state 
issued permits and tax registration, the federal government clearly 
prevented California from implementing its own laws.133  The court 
addressed the Supremacy Clause in a footnote, merely noting that § 542 
did “not provide immunity from Federal prosecution”, and that no state 
law actually legalizes the “possession, distribution, or manufacturing of 
marijuana.”134  While the CSA remains in effect, states cannot authorize 
activity that remains prohibited by federal law.135 
The court engaged in statutory interpretation to determine if there 
truly was a constitutional violation of the appropriations bill by including 
the Amendment.136  The court emphasized that under appropriations law, 
it could only consider the text of the Amendment, not any “expressions of 
intent” from any legislative history.137  Unless otherwise defined, the court 
stated, “words will be interpreted as taking their ordinary, contemporary, 
common meaning.”138 After assessing the common meaning of the words 
“them”, “their own laws,” and “implement,” the court found that § 542, as 
written, prohibits the DOJ from financing actions that impact medical 
marijuana states from giving practical effect to their own laws authorizing 
the use, distribution, possession, or cultivation of medical marijuana.139  In 
its defense, the DOJ unsuccessfully argued that by taking action against 
private individuals and not against the states themselves, it was not in 
violation of the Amendment, and it was not preventing states from 
enforcing their own laws.140  The court stated that the DOJ, by taking 
actions against individuals as opposed to states, prevented the states from 
giving effect to their own laws that specifically provide for “non-
prosecution of individuals who engage in permitted conduct.”141 
It is important to note that the court was explicit in stating two 
principles: (1) that § 542 only applies to lawful medical marijuana use, 
distribution, and cultivation; and (2) that it applies to a wide variety of 
                                                                                                                                     
 132 McIntosh, 833 F.3d at 1175. 
 133 Def.’s Motion to Dismiss at 5, McIntosh, 833 F.3d 116. 
 134 McIntosh, 833 F.3d at 1179, n.5. 
 135 Id. 
 136 Id. 
 137 Id. at 1178. 
 138 Id.  at 1175 (citing Sandifer v. U.S. Steel Corp., 134 S. Ct. 870, 876 (2014)). 
 139 Id. at 1176. 
 140 McIntosh, 833 F.3d at 1176. 
 141 Id. at 1176–77. 
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laws in flux,142 limiting power of the executive branch to some extent.143  
To establish these principles, the court returned to interpreting the 
Amendment, finding that the ordinary meaning of the Amendment 
restricts the DOJ from allowing states to implement their laws that only 
authorize medical marijuana use. 144 
The court emphasized that no state law may legalize “possession, 
distribution, or manufacturing of marijuana.”145  In remanding the case,146 
the court did not provide much guidance for district courts who must 
determine the precise remedy “in the first instance and in each case.”147  
The decision tipped its hat to Gonzales in a footnote by stating: “[u]nder 
the Supremacy Clause of the Constitution, state laws cannot permit what 
federal law prohibits.  Thus, while the CSA remains in effect, states cannot 
authorize the ‘manufacture, distribution, or possession of marijuana’. Such 
activity remains prohibited by federal law.”148 
This decision is not necessarily a political one. The ruling on the 
basis of the law itself does not cater to one side or another, especially given 
the support for the Amendment,149 but rather looks strictly to the plain-
meaning of words at issue in the Amendment as opposed to outside intent, 
a factor which could otherwise persuade a judge if he or she agrees with 
such intent.150 McIntosh makes clear that the issues from Gonzales are still 
present even though, more than a decade later, states continue to legalize 
marijuana through the democratic process.151 
                                                                                                                                     
 142 Perhaps referring to state recreational laws in effect across the country. 
 143 McIntosh, 833 F.3d at 1178. 
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 145 Id. at 1179, n.5. 
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 151 See Steve Birr, Activists Hopeful Marijuana Ballots Will Spark Nationwide Reform, 
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C. Congress and the Executive Branch post-McIntosh 
Section 542 is a clever workaround to the CSA.  In addressing this 
apparent contradiction, the Ninth Circuit concluded that the DOJ can still 
prevent states from implementing medical marijuana laws that violate 
federal law, despite any medicinal purposes or state-wide acceptance.152  
What the DOJ cannot do, however, is spend a penny to prosecute 
individuals in states with valid medical marijuana laws if those laws are 
being followed.153  The DOJ, however, is not rendered completely 
powerless in light of this ruling; it is merely prevented from spending 
funds to prosecute.154  The agency is not in violation of the Farr-
Rohrabacher Amendment if it pursues individuals, for example, who 
engage in marijuana-related conduct in states without protective laws.155  
Additionally, the agency is free to spend the funding allotted to make it 
more difficult for states’ medical marijuana programs to function even 
under state law by increasing oversight, investigation, and surveillance of 
growers, dispensaries, possibly patients, and the resources necessary for 
businesses to survive.156  Equally as important, the Amendment does not 
limit the DOJ from using funds to prosecute in states that do not have 
medical marijuana laws.157 
The Ninth Circuit was very aware of Congress’s ability to control 
federal purse-strings, foreshadowing that “this temporary lack of funds” 
could continue if Congress decides to include the Amendment in future 
bills.158  President Obama did extend the Amendment when he signed into 
law the 2017 Continuing Appropriations and Military Construction, 
Veterans Affairs, and Related Agencies Appropriation Act.159  The Act 
does not contain the exact language of the Amendment but does state that 
funds previously made available under provisions in the 2016 measure are 
to be extended.160  There is no specific wording allowing previously 
untouchable United States Treasury funds to be made available to the DOJ 
                                                                                                                                     
 152 McIntosh, 833 F.3d at 1176. 
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 154 See supra note 99 at § 542. 
 155 McIntosh, 833 F.3d at 1178; see also Lino S. Lipinksy and Joel M. Pratt, Congress’ 
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to prosecute medical marijuana claims under the CSA.161  The DOJ is 
forced to pick and choose its battles, as it cannot spend federal funds to 
prosecute individuals who lawfully engage in permissible conduct under 
state law.162  If the federal government does choose to prosecute, according 
to the McIntosh court, “it has prevented the state from giving practical 
effect to its law providing for non-prosecution of individuals who engage 
in the permitted conduct.”163 
It is also clear that there is no protection afforded by the Amendment 
alone in the face of federal enforcement, even if the states allow for 
medical marijuana use: 
The . . . observation should also serve as a warning.  To be 
clear, § 542 does not provide immunity from prosecution for federal 
marijuana offenses. The CSA prohibits the manufacture, distribution, and 
possession of marijuana. Anyone in any state who possesses, distributes, 
or manufactures marijuana for medical or recreational purposes (or 
attempts or conspires to do so) is committing a federal crime. The federal 
government can prosecute such offenses for up to five years after they 
occur.164 
Congress “chose to proscribe preventing states from implementing 
laws that authorize the use, distribution, possession, and cultivation of 
medical marijuana,” but this is not a fixed or a permanent stance.165 As it 
stands, neither meaningfully changes marijuana’s status under federal law 
nor does it restrain the executive branch from enforcement.166  Even 
though the appropriations bill was extended, the Amendment could be 
taken out in the next iteration, or Congress may change its mind entirely 
and appropriate funds for prosecutions if and when it so chooses.167 
Moreover, because of how controversial the Amendment is, a court 
in a different jurisdiction could interpret the statute differently and hold 
the opposite of the Ninth Circuit.168  Any decision regarding marijuana is 
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not Congress’s alone, either.169  The Ninth Circuit is cognizant that a new 
administration could also shift the nation’s priorities, casting more 
ambiguity on the future of medical marijuana.170  With the Cole and Ogden 
memos providing states with some assurance that the federal government, 
at least under the Obama Administration, would not enforce the marijuana 
prohibition in every instance, it is no surprise that the Farr-Rohrabacher 
Amendment reflects the Obama Administration’s view on medical 
marijuana consistent with its DOJ memos.171 
V. MEDICAL MARIJUANA IN THE FUTURE 
Medical marijuana has had a long, strange trip172  in Washington but 
where shall it go next? Writing in 2011, Professor Martin D. Carcieri of 
San Francisco State University stated that he expected federal marijuana 
prohibitions to reach a tipping point in 2013 and that, because Congress 
was failing to take the lead on the matter, it would have to yield—most 
likely—to the states.173  Four years and one administration change later, 
the new Commander-In-Chief has options, assuming that Congress 
extends the Farr-Rohrabacher Amendment beyond 2017.  Subsection A 
will discuss the options before the new administration and the likelihood 
of success for each.  Subsection B will advocate for keeping the status quo 
from the Obama Administration to allow for additional scientific research 
in order to form a more educated decision on the future status of medical 
marijuana. 
A. The Trump Administration’s Options 
President Trump appointed several anti-marijuana figures to his 
administration and while he was swift to act on issues such as abortion174 
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and immigration,175 as of the writing of this Comment, there is no official 
support for or rejection of medical marijuana.  Two individuals in 
particular play a decidedly large role in the future of marijuana, regardless 
of whether they remain with the administration or not. Attorney General 
Jeff Sessions stated on record that marijuana is a gateway drug.176  He also 
said that marijuana legalization should be resisted, yet he has not provided 
any specific plans to challenge state-regulated markets.177  Attorney 
General Sessions previously criticized President Obama during a Senate 
hearing for his admission of smoking marijuana in high school.178  Tom 
Price, the Former Secretary of HHS, was also a marijuana opponent.179 
John Hudak of the Brookings Institution has stated that Price has 
consistently voted against marijuana policy reforms, even those modest 
ones, and the medical community, of which Price is a part, is conservative 
about the use of marijuana.180  Interestingly, although Secretary Price, then 
a congressman, voted against various measures that would have  prevented 
the DOJ from interfering with state medical marijuana laws, during his 
tenure Price did support “a limited measure preventing the DOJ from 
interfering with states that allow the medical use of cannabidiol.”181 
Despite his resignation, President Trump could seek to fill the position 
with someone with similar views to Former Secretary Price to suggest 
status quo on the issue. 
Throughout his campaign and through mid-2017, President Trump 
distinguished medical marijuana from recreational marijuana, expressed 
support for medical marijuana, and stated that legalization should be 
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implemented on a state-by-state basis.182  In May 2017, his signing 
statement pertaining to the passing of the Consolidated Appropriations Act 
of 2017, 183 which upheld the Farr-Rohrabacher Amendment through 
September 2017, conflicted with his previously expressed views.184  In the 
short paragraph addressing medical marijuana, President Trump stated 
that, he “will treat this provision consistently with [his] constitutional 
responsibility to take care that the laws be faithfully executed.”185 
 The implication that President Trump could disregard the bill’s 
limits on the use of DOJ money is nonsensical.186 Steve Bell, a Senior 
Advisor at the Bipartisan Policy Center, stated that “[i]t is the 
constitutional prerogative of the Congress to spend money and to put 
limitations on spending,” and that President Trump’s signing statement is 
“an extremely broad assertion of executive branch power over the 
purse.”187 
Attorney General Sessions has been an outspoken opponent of 
marijuana, including its use for medicinal purposes.  He made headlines 
in the summer of 2017 for personally asking Congress to let him prosecute 
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medical-marijuana providers.188  In his May 1, 2017 letter, Attorney 
General Sessions expressed his concern about the McIntosh decision, by 
citing to a historic drug epidemic, the uptick in violent crimes, and an 
alleged link between marijuana and the increased risk of psychiatric 
disorders.189  The justification of a drug “epidemic,” however, does not 
comport with actual data.190  For example, in January 2017, the National 
Academies of Science, Medicine and Engineering found strong evidence 
suggesting that marijuana is effective in dealing with chronic pain in 
adults, as compared to a placebo.191  Attorney General Sessions may be 
overstating the alleged danger of marijuana.  While it may be habit-
forming, marijuana is significantly less addictive than opiates and has no 
known lethal dosage192 (although earlier studies relied upon dosages given 
to animals),193 unlike opiates.  For chronic pain, many medical 
professionals prescribe opiates, which have a high risk of abuse and 
overdose.194  In 2013 alone, it was estimated that 1.9 million people either 
“abused or were dependent on prescription opiates.195  In 2014, a study 
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showed that states that allowed for medical marijuana use between 1999 
and 2010 had, on average, nearly 25% fewer opiate overdose deaths 
compared to those states without.196  This study, however, has its limits in 
that it is purely observational and only looks at the “correlation between 
medical marijuana uptake and opiate deaths”; it is not “able to say that the 
former definitively caused the decline in the latter.”197  One year later, the 
National Bureau of Economic Research found that states with medical 
marijuana dispensaries had a 15-35% decrease in “admissions to substance 
abuse centers” and also saw a similar decline in deaths caused by opiate 
overdose.198  Additionally, last year, another study reported that 
individuals who used medical marijuana were “64 percent less likely to 
report opiate use” and negative medical side effects and more likely to 
report a good quality of life.199 
Attorney General Sessions is not just up against public support for 
medical marijuana,200 but he is also up against Congress.  In July 2017, the 
“Senate Appropriations Committee approved the Farr-Rohrabacher 
Amendment by a voice vote”, meaning that the panel, including sixteen 
Republicans, did not find the measure controversial.201  This is not 
necessarily an issue of partisanship, as the Republican-controlled congress 
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has already included the measure in previous bills.202  Moreover, there 
have been other congressional measures introduced that would expand the 
Amendment including those that would allow “Department of Veterans 
Affairs doctors to counsel patients on the use of medical marijuana”, those 
that would even “legalize marijuana at the federal level”, and those that 
would modify the “classification of marijuana to allow” precisely for what 
this comment is advocating for: research.203 
Despite this, in September 2017, the U.S. House Rules Committee 
blocked the Farr-Rohrabacher Amendment, now known as the 
Rohrabacher-Blumenauer amendment.204  However, President Trump and 
Democratic leaders reached a budget agreement, which, among other 
things, would extend the rider through December 2017.205  Unsurprisingly, 
in order to avoid a government shutdown, Congress passed an emergency 
resolution which extended the amendment, amongst other spending 
provisions.206 This extension could help cannabis business owners come 
into compliance with state laws without much threat of federal 
enforcement.207  However, even if the Amendment is not renewed for the 
next fiscal year, Attorney General Sessions could still try to shut down 
state-licensed medical marijuana suppliers.208  In response to the House 
Committee’s actions, Representatives Blumenauer and Rohrabacher 
stated that: 
By blocking our amendment, Committee leadership is putting at risk 
the millions of patients who rely on medical marijuana for treatment, as 
well as the clinics and businesses that support them. This decision goes 
against the will of the American people, who overwhelmingly oppose 
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federal interference with state marijuana laws. These critical protections 
are supported by a majority of our colleagues on both sides of the aisle. 
There’s no question: If a vote were allowed, our amendment would pass 
on the House floor, as it has several times before.209 
President Trump has, so far, focused his policy agenda on other 
issues despite his own expressed desire that states be allowed to decide if 
marijuana is right for them. Given his work with Democratic leaders, there 
could be hope. The administration has several options. First, the Trump 
Administration could actually increase enforcement of marijuana 
prohibitions in a variety of ways.210  Under this approach, there is likely to 
be strong pushback from the states regardless of whether the Amendment 
is included or not in the budget.  Any attempts at prosecuting individuals 
in states with valid medical marijuana laws would likely violate the Ninth 
Circuit’s holding in McIntosh, even though the court insulated itself by 
specifically stating that policies can change and assumed no congressional 
action would change the Amendment.211  Individuals in the marijuana 
industry, however, are hopeful that the Trump Administration realizes any 
crackdown against “broadly popular laws” in states will create political 
issues, and it should instead focus on other areas.212   Even if existing 
markets are left alone, new states may be blocked or delayed from 
legalizing medical marijuana by excluding those states from the 
Amendment in any future version or by being intentionally vague on the 
issue to keep state legislatures in abeyance.213 
If the Amendment is not included in any future budgets, this could be 
problematic for suppliers and individuals who rely on medical marijuana, 
but it does not take away from the legality of the Ninth’s Circuit’s ruling.  
The issue was brought to the judicial forefront and it is still a pressing 
issue.214 The disconnect amongst the branches will undoubtedly create a 
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vacuum.  Such a vacuum will cause constitutional tension and a possible 
showdown with the Trump administration by impacting states’ abilities to 
give effect to their own laws.215   Justice O’Connor’s dissent in Gonzales 
makes specific mention of the fact that because the state citizens 
themselves voted for such measures, the federal government should not 
interfere with the state’s choice.216  There is concern over whether there 
will be enough votes to carry the Amendment into the future. Under 2017 
House leadership, there has been a restriction regarding the scope of policy 
riders to be considered in conjunction with the rule under which spending 
bills are considered.217   In the event that the federal government chooses 
not to incorporate the Amendment again, the protection ceases to exist, 
which could set the medical marijuana industry back, even with state 
authorization and public approval.218  There are organizations219 and 
individuals on both sides of the political aisle that are fighting to ensure 
state medical marijuana laws are honored under the Trump 
administration.220 Disturbing the will of the people could drag the country 
to court, forcing a divided Supreme Court to make the ultimate decision. 
The Trump Administration’s second option is to keep the status quo 
established by the Obama Administration’s DOJ memos and the passage 
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the executive branch would operate under the Obama-era internal 
guidance and would provide for minimal federal intrusion.  Even though 
the DEA already refused to reclassify marijuana once, President Trump 
changed his stance on various issues since his inauguration, a fact that 
could prove useful to medical marijuana advocates. 
A task force, comprised of prosecutors and federal law enforcement 
officials, assembled by Attorney General Sessions himself may have 
already started down this track.  As of August 2017, the Task Force on 
Crime Reduction and Public Safety has not offered new policy 
recommendations to advance Attorney General Sessions’ anti-marijuana 
views and in fact, it encourages continued research to determine whether 
the Obama-era hands-off policy should be changed or rescinded.222  Pride 
may also be at play, as John Hudak of the Brookings Institute notes: “If 
they come out with a more progressive, liberal policy, the attorney general 
[sic] is just going to reject it.  They need to convince the attorney general 
that the recommendations are the best they can do without embarrassing 
the entire department by implementing a policy that fails.”223  Despite 
Attorney General Sessions’ plea to Congress, the report “says officials 
should continue to oppose rules” blocking the DOJ from interfering states 
that allow for medical marijuana use and distribution where it is 
allowed.224  Even with letters sent to the governors of Colorado and 
Washington asking how the states would address reports of their 
inadequacy in regulating marijuana,225 some members of Congress are not 
worried about a change.  They pointed to comments the Attorney General 
made during his Senate confirmation, whereby he stated his opposition to 
legalizing marijuana, but added the caveat that he understands the limited 
federal resources, echoing those Democrats before him.226  The 
recommendations were provided on a rolling basis but nevertheless, 
Attorney General Sessions has been preparing to target legal cannabis in 
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at least three of the eight states that have legalized recreational 
marijuana.227 
The status quo alleviates pressure on the Supreme Court to resolve 
this controversial issue. A potential circuit split could occur depending on 
what the state laws are at the time of a decision. For example, a medical 
marijuana decision appealed to a post-McIntosh Ninth Circuit may not be 
the same as a medical marijuana case appealed to the Sixth Circuit.228  The 
Supreme Court would probably not take up another medical marijuana 
case absent a circuit split, especially in light of strong public support, 
despite a Republican-controlled federal government.229  If the Court does 
take a case, it should do so on a non-partisan basis, a concept not so 
farfetched given the Ninth Circuit’s ruling in McIntosh.  Should the Court 
ultimately decide to hear a case and rule against the Amendment, this may 
not stop states from continuing to legalize medical marijuana, as has been 
the case post-Gonzales, which would only drag out the state-federal 
government tension.  Thus, the burden is on Congress to either amend the 
CSA or exempt the substance all together, provided the states can show 
successful and legal use of medical marijuana and can offer valid and 
reliable results from such use.230 
Third, the new administration could take steps to legalize medical 
marijuana independent of legalizing recreational marijuana more 
generally.  The third option is, in a way, the end result of option two.  
Option three cannot, and certainly will not happen, without strong and 
convincing evidence that medical marijuana should be considered a 
legitimate form of medical relief.  The DOJ memoranda allowing states to 
continue experimenting with legalized medical marijuana or Congress 
choosing to remove marijuana, or at least medical marijuana, from 
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Schedule I could create thousands of jobs nationwide.231  Moreover, there 
could be more economic benefits, such as fees and taxes generated from 
allowing the states more freedom to experiment with operating under a 
legalized medical marijuana system.232 
B. A Scientific Argument for the Status Quo 
This Comment posits that the best approach is a scientific one.  It is 
scientifically more productive to keep the status quo in terms of 
enforcement, allowing for the opportunity for new research channels either 
by expanding those eligible to conduct that research, or by allowing states 
to spend their own funds to carry out such studies.  The federal 
government’s monopoly on research and its refusal to privatize FDA-
approved research has severely hampered researchers’ attempts to 
legitimize marijuana as a legal prescription medicine.233  If Congress does 
not want to expand the number of individuals or corporations eligible for 
researching the drug using any federal funding, it can let the states provide 
funding.  By doing so, the states would be able to provide closely 
monitored, in-depth studies as to the efficacy of medical marijuana. 
State institutions and agencies, such as medical boards, departments 
of healthcare services, public universities, and research hospitals would be 
the ideal battle labs for such studies.  In fact, a recent study showed that 
medical provides were the ability to prescribe medical marijuana to 
patient, including children, “strong supported clinical trials to investigate 
its use [particularly, for example,] in children.”234 By granting more access 
to engage in clinical trials, Congress would be able to make an intelligent 
decision based upon ample results, allowing it to either amend the CSA to 
provide an exception for medical marijuana or to uphold its prohibition.  
If the states were paying for research facilities and operations with their 
own revenue, they would more easily provide expanded medical 
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marijuana-based services to their own citizens without having to request 
any assistance from the federal government.235 
This approach also follows the strong federalism expressed by 
Justice O’Connor’s dissent in Gonzales.236  This dissent is important 
because it provides the best solution for obtaining the best results to make 
the best choice about marijuana.  It also would allow states to operate 
without pressure from potential federal enforcement even if they are 
following their own laws.237  Even though states have passed medical 
marijuana legislation, they are kept in abeyance of federal prosecution and 
are left wondering if, or rather when, the federal government will enforce 
the CSA against citizens who lawfully abide by the state measures.  
Allowing states to give effect to their own laws while the federal 
government stays in abeyance would alleviate the possibility of fruitless 
government intervention.  If Congress is content with the results arising 
out of the states after a reasonable and appropriate period of observation 
and monitoring, it could expand the Farr-Rohrabacher Amendment to 
include all states. 
Alternatively, the DOJ could issue new guidance to ensure the states 
and the federal government understand each other’s positions and can 
operate relatively freely under the current administration.238  President 
Trump has already proven to be flexible on his campaign rhetoric and his 
ever-active Twitter account, and as of December 2016, produced no 
mention of the word “marijuana”.239  Before the appointment of Attorney 
General Sessions, marijuana opposition was removed from the White 
House website, suggesting that maintaining the status quo will allow the 
administration to focus on other priorities, and save the government the 
money and effort required to fight an unnecessary drug war.240 The Farr-
Rohrabacher (now Rohrabacher-Blumenauer) Amendment helps check 
the government and should remain as is for the time being. Allocating 
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funds to raid businesses that are operating validly under state law will 
likely anger constituents of members of Congress from marijuana states 
from marijuana states.241 
Science is the best and most effective way to address the legalization 
of marijuana.  We live in a time of scientific uncertainty.  Agencies, and 
the scientific community more broadly, are under a tremendous amount of 
scrutiny.242  Even more than the attack on science is the attack on the health 
of seriously ill Americans who, because of federal oversight, may be 
denied alternative treatment options, exacerbating already debilitating 
illnesses.  In cases like Charlotte Figi’s,243 parents are forced to keep their 
children on strong pharmaceuticals that may cause severe side effects and 
offer only marginal relief.244  In 2017, Melvin Washington, a retired NFL 
player; Alexis Bortell, an eleven-year-old girl with severe epilepsy; and 
Jose Belen, a disabled veteran with PTSD, filed suit against Attorney 
General Sessions, the DEA, and the DOJ over the constitutionality of the 
CSA and the listing of marijuana as a Schedule I drug.245   The suit alleges 
that by classifying cannabis as a Schedule I drug, methamphetamines and 
cocaine (Schedule II drugs) are considered more benign than marijuana 
thus rendering the classification “irrational” and in violation of the 
Constitution.246  In light of this irrationality, “the federal government is 
aware that the system is flawed,” according to the plaintiffs.247 
This Comment suggests that there could be potential medicinal 
benefits from marijuana more broadly, and not just from low-THC medical 
cannabis.248  Limiting research in this way poses serious consequences for 
those with no other option.  Moral opposition to marijuana does not 
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preclude positive scientific results.  For the federal government to say 
there is no medical benefit249 while restricting research, as opposed to 
allowing private entities or state-funded agencies,250 universities, or 
hospitals to research is to effectively not “pass the pipe” of research.251 
Private pharmaceutical firms and state-institutions would be ideal 
experiment laboratories because of non-federal funding.  In keeping its 
monopoly over research outlets, the federal government is harming those 
who could benefit from marijuana medically. 252   In coveting research, 
there can be no progress in the scientific or medical communities. 
VI. CONCLUSION 
This Comment advocates for the government to formally allow for 
more private and state-funded research opportunities.  If Congress feels 
compelled to regulate this, it would be beneficial to at first allow states 
with medical marijuana laws to do such research.  Congress could provide 
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the oversight and guidelines to those private and state actors studying 
marijuana but, before it can do that, it must be clear in its decision to 
suspend enforcing the CSA in order to alleviate the threat of possible 
enforcement, which was discretionary under the Obama Administration. 
If enforcement continues to be discretionary under the Trump 
Administration, there must be guidance as to which states may participate 
in and fund this scientific research.  Only then will Congress be able to 
once and for all remove medical marijuana from the Controlled Substance 
Act. 
There is no way to make an intelligent decision about medical 
marijuana without allowing for all research avenues to be explored.  
Advancing society can only be done by advancing scientific objectives 
anything short of that cripples the future, whether it is with regard to 
medical marijuana as a federally permissible treatment option or more 
generally. Science is vital to societal progression.  Medical marijuana is 
progress for those who are out of treatment options for serious illnesses or 
may even open the door to other medicinal capabilities.  Medical 
marijuana has a place in society as well, as demonstrated by continuously 
growing state and public support.253  When medical marijuana is 
distributed in accordance with state law, it is properly prescribed, and that 
is progress. The current consensus in the country leans towards support for 
medical marijuana;254 there is just a difference in the details as to how it 
should be legalized and regulated.  In order to get to a point where 
marijuana is properly distributed and regulated, the federal government 
must turn to science.  Science can help raise awareness about marijuana’s 
effectiveness, or it could show that it is not helpful.  Without research, 
however, there is no way to know for sure. 
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